A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the safety of VAC85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (MPNs).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dose Escalation Participants with essential thrombocythemia (ET) and myelofibrosis (MF) will receive VAC85135 target dose intramuscular (IM) injection in the safety lead-in cohort (Cohort 0). Participants in subsequent cohorts will receive VAC85135 target dose IM injection along with ipilimumab intravenous (IV) infusion. Ipilimumab dose may be escalated based on dose limiting toxicity (DLT) observations. |
Biological: VAC85135
Participants will receive VAC85135 as IM injection.
Drug: Ipilimumab
Participants will receive Ipilimumab as IV infusion.
|
| Experimental: Dose Expansion Participants with polycythemia vera (PV) or post-polycythemia vera myelofibrosis, ET and MF will receive VAC85135 target dose IM injection with ipilimumab IV infusion at the dose(s) determined by study evaluation team (SET). |
Biological: VAC85135
Participants will receive VAC85135 as IM injection.
Drug: Ipilimumab
Participants will receive Ipilimumab as IV infusion.
|
Outcome Measures
Primary Outcome Measures
- Number of Participants With Dose-limiting Toxicity (DLT) [Baseline (Day 1) up to Day 78]
Number of participants with a DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. Toxicities will be graded for severity according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [Up to 76 weeks]
Number of participants with AEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical product. AEs will be graded as Grade 1: Mild- asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2: Moderate- minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL); Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4- Life-threatening consequences- urgent intervention indicated; Grade 5: Death related to AE.
Secondary Outcome Measures
- Number of Participants With Antigen-specific T-cell response [Up to end of treatment (EOT) (Up to 64 weeks)]
Number of participants with antigen-specific T-cell response will be reported.
- Number of Participants With Overall Response per Revised Response Criteria by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) Consensus Report [Up to 76 weeks]
Overall response will be measured by complete remission, partial remission, clinical improvement, anemia response, spleen response, symptoms response, progressive disease, stable disease and relapse as per the revised IWG-MRT and ELN response criteria for myelofibrosis (MF).
- Number of Participants Disease Response at Weeks 24, 48 and End of Treatment (EOT) per Modified IWG-MRT Criteria [Weeks 24, 48 and EOT (64 weeks)]
Number of participants with disease response as per the modified IWG-MRT criteria will be reported.
- Number of Participants With Peripheral Blood Mutant Calreticulin (mutCALR) and Janus Kinase 2 With V617F Mutation (JAK2V617F) Allele Burden [Up to end of treatment (EOT) (Up to 64 weeks)]
Number of participants with peripheral blood mutCALR and JAK2V617F allele burden will be reported.
- Number of Participants With Transfusion Burden [Up to end of treatment (EOT) (Up to 64 weeks)]
Number of participants with transfusion burden will be reported.
- Number of Participants With Patient-reported Symptoms on Therapy [Up to end of treatment (EOT) (Up to 64 weeks)]
Number of participants with patient-reported symptoms on therapy will be reported.
- Time to Progression of Myeloproliferative Neoplasms (MPNs) [Up to end of treatment (EOT) (Up to 64 weeks)]
Time to progression of MPNs (polycythemiavera [PV], essential thrombocythemia [ET], and primary myelofibrosis [PMF]) will be reported.
- Time to Initiation of Next Therapy [Up to 76 weeks]
Time to initiation of next therapy for myeloproliferative neoplasms (MPNs) will be reported.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Have an Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 or 2
-
Have the following hematologic laboratory values: Leukocytes greater than or equal to (>=) 1.510^9 per liter, Neutrophils >=1.0109 per liter, Platelets >=20*109 per liter, Hemoglobin greater than (>) 7 gram per deciliter (g/dL)
-
Have the following chemistry laboratory values: Alanine aminotransferase (ALT): less than or equal to (<=) 3upper limit of normal (ULN), aspartate aminotransferase (AST): <=3ULN, total bilirubin: <=1.5*ULN, and glomerular filtration rate >=40 milliliter per minute (mL/min)
-
A female participant of childbearing potential must agree to all the following during the study and for 6 months after the last dose of study treatment: use a barrier method of contraception, use a highly effective preferably user-independent method of contraception, not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction, not plan to become pregnant, not to breast-feed
-
A male participant must agree to all the following during the study and for 90 days after the last dose of study treatment: wear a condom when engaging in any activity that allows for passage of ejaculate to another person, not to father a child, not to donate sperm or freeze for future use for the purpose of reproduction
Exclusion Criteria:
-
History of any significant medical condition per investigators judgment (example: severe asthma/chronic obstructive pulmonary disease (COPD), poorly regulated heart condition, insulin dependent diabetes mellitus)
-
Serious known clinically relevant allergies or earlier anaphylactic reactions
-
Currently pregnant or breastfeeding
-
Prior treatment with any Janus kinase 2 (JAK2) inhibitor
-
Known sensitivity or contraindications to the use of Ipilimumab per local prescribing information
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | The University of Alabama at Birmingham | Birmingham | Alabama | United States | 35233 |
| 2 | Mayo Clinic Cancer Center-Scottsdale | Phoenix | Arizona | United States | 85054 |
| 3 | City of Hope | Duarte | California | United States | 91010 |
| 4 | Moffitt Cancer Center | Tampa | Florida | United States | 33612 |
| 5 | Cleveland Clinic | Cleveland | Ohio | United States | 44195 |
| 6 | University of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 |
| 7 | Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) | Nashville | Tennessee | United States | 37232-0021 |
| 8 | MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
| 9 | University Health Network (UHN) Princess Margaret Cancer Centre | Toronto | Ontario | Canada | M5G 1Z5 |
| 10 | Hosp. Clinico Univ. de Salamanca | Salamanca | Spain | 37007 | |
| 11 | Hosp. Clinico Univ. de Valencia | Valencia | Spain | 46010 |
Sponsors and Collaborators
- Janssen Research & Development, LLC
- Bristol-Myers Squibb
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR109149
- 2021-006033-20
- VAC85135MPN1001